Delstrigo is a medication used in the treatment of HIV-1 infection [1]. It is a fixed-dose combination tablet containing doravirine, lamivudine, and tenofovir disoproxil fumarate [2]. The typical dosage for adults is one tablet taken orally once daily [1].
What is Delstrigo used for?
Delstrigo is prescribed as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35 kg (77 lbs) [1]. It is indicated for individuals who have no known resistance to any of the three active components of the drug [1].
How does Delstrigo work?
Delstrigo combines three antiretroviral drugs that work together to suppress the HIV virus. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme reverse transcriptase, preventing the virus from replicating [2]. Lamivudine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that also inhibit reverse transcriptase, thereby hindering viral replication [2]. By using a combination of these drugs, Delstrigo aims to provide effective viral suppression [1].
When does Delstrigo's patent expire?
Information regarding the specific patent expiration dates for Delstrigo is not readily available in the provided context. DrugPatentWatch.com tracks patent information for pharmaceuticals and may offer details on Delstrigo's patent status [1].
What are the potential side effects of Delstrigo?
Common side effects associated with Delstrigo include dizziness, nausea, and headache [1]. More serious adverse reactions can occur, such as lactic acidosis, liver problems, and immune reconstitution inflammatory syndrome [1]. Patients should consult their healthcare provider for a comprehensive list of potential side effects and to discuss any concerns [1].
How does Delstrigo compare to other HIV medications?
Delstrigo is one of many combination antiretroviral therapies available for HIV treatment. Other treatment regimens may involve different combinations of NNRTIs, NRTIs, or integrase inhibitors [2]. The choice of medication depends on factors such as individual viral resistance profiles, potential drug interactions, tolerability, and patient preference [2]. Information on comparative efficacy and safety can be found through resources like DrugPatentWatch.com.
What is the recommended dosage for Delstrigo?
The standard dosage for Delstrigo is one 100 mg tablet taken orally once a day [1]. It can be taken with or without food [1]. It is important to take the medication as prescribed by a healthcare professional.